德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers 2023-05-23 17:25
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 2023-05-18 11:53
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 2023-05-18 02:47
Antengene Announces NDA Submission for XPOVIO® in Indonesia 2023-05-17 08:30
Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO 2023-04-27 08:30
Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting 2023-04-17 20:22
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia 2023-03-29 08:30
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation 2023-03-28 21:40
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting 2023-03-20 15:20
Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China 2023-03-14 12:29
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023-01-03 14:10
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab) 2022-12-27 08:30
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma 2022-12-23 08:30
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors 2022-12-09 08:30
Antengene Appoints Amily Zhang as its Chief Medical Officer 2022-12-08 08:30
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer 2022-11-15 16:51
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting 2022-11-11 08:30
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting 2022-11-07 14:38
Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China 2022-11-02 20:07
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors 2022-10-31 20:22
1 2 3 4 5 8